News

Most recently, Dr Hensby served as the vice president of R&D and regulatory affairs for Ivrea Pharmaceuticals. Dr Hensby is a graduate BSc in pharmacology from Kings College,

The initial data from the multiple myeloma study show that HGS-ETR1 was well tolerated and suggest that disease response was comparable for this combination versus bortezomib alone. The

The combination is expected to create a company with $1.6 billion in annual sales with a significantly expanded global footprint. The combined company will be known as ConvaTec

Ipsogen SA has also appointed Ms Hertzberg as its vice president of corporate business development. Immediately prior to joining Ipsogen, Ms Hertzberg served as general manager of global

The Petal study enrolled 252 patients, with a confirmed diagnosis of endometriosis, into three treatment groups – elagolix 150mg once daily, elagolix 75mg twice daily, or depo-subQ provera

The agreement grants Dr Reddy’s exclusive rights to distribute Cosmederm Technologies’s unique skin care products throughout India. Cosmederm’s proprietary technology allows for the formulation of highly potent, non-irritating

The study compared the current standard of care for acute coronary syndrome (ACS), including aspirin and clopidogrel, with apixaban on top of the standard of care. The six-month

However, GlaxoSmithKline (GSK) is retaining rights to Entereg for postoperative ileus (POI), and the companies will continue to collaborate on the development and commercialization of Entereg for POI

Olympia is designed to analyze real-world clinical outcomes data for Boston Scientific’s second-generation Taxus Liberte paclitaxel-eluting coronary stent system in the treatment of patients with coronary artery disease.